JUN 22·SEC EDGARLow
Teleman Dan Benjamin purchased $20K of NSRX
Teleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.
StockNYSE · US · USDHealthcare · DRUG MANUFACTURERS - GENERAL
$NSRX
Nasus Pharma Ltd
Price · $NSRXvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $NSRX in the last 7 days.
Insider · 30dAll trades →
No SEC Form 4 filings for $NSRX in the last 30 days.
See all $NSRX insider activity →Top stories · $NSRXMore →
MAY 1·Yahoo! Finance Canada
Nasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.
APR 8·Stock Titan
Funicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)
Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.
NSRX sentiment & insider activity
Recent NSRX coverage spans financial news and insider activity.
What's driving NSRX
Insider buying can be a modest sentiment tailwind, but this is not a fundamental catalyst like guidance, trial data, or financing.
Nasus Pharma's participation in investor conferences signals ongoing investor engagement but has limited immediate trading impact.
The passive investment by Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver suggests a neutral to slightly positive outlook on NSRX, potentially signaling confidence without aggressive activism.
The appointment of Eyal Rubin as EVP and CFO signals strategic leadership strengthening, potentially leading to improved financial management and operational focus.
Nasus Pharma announced the initiation of a Phase 2 clinical trial for NS002, indicating progress in its drug development pipeline. This development could positively influence the company's valuation and investor sentiment.
alphai scores every news story that mentions NSRX with an AI model for sentiment and relevance, and aggregates insider trades from Nasus Pharma Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $NSRX
Score
Teleman Dan Benjamin purchased $20K of NSRX
Teleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.
2 min readNasus Pharma to Participate in Upcoming Investor Conferences
Nasus Pharma, a clinical-stage pharmaceutical company, announced its participation in two upcoming investor conferences in May 2026. CFO Eyal Rubin will attend the "Market Movers Investor Summit" and the "D. Boral Capital Global Conference" in New York, engaging in one-on-one meetings with interested investors. The company focuses on developing innovative intranasal products, including NS002, an intranasal epinephrine product for anaphylaxis.
2 min readFunicular Funds, Cable Car Capital stake 5.2% in Nasus Pharma (NSRX)
Funicular Funds, Cable Car Capital, and Jacob Ma-Weaver have collectively reported a 5.2% beneficial ownership stake in Nasus Pharma Ltd (NSRX), totaling 612,913 Ordinary Shares each. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment. The ownership calculation is based on 11,710,808 shares outstanding as of March 27, 2026.
2 min read
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer - Nasus Pharma (AMEX:NSRX)
TEL AVIV, Nov. 20, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma", "Nasus" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the appointment ...
2 min readNasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed - Nasus Pharma (AMEX:NSRX)
The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector
3 min readNasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder - Nasus Pharma (AMEX:NSRX)
TEL AVIV, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Nasus Pharma Ltd. ( NYSE:NSRX ) ( "Nasus Pharma" or the "Company" ) , a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently ...
2 min read